DHT Holdings Inc. vs Cassava Sciences Inc — how do they compare? DHT Holdings Inc. trades at $24.65 (market cap $4.02B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: DHT Holdings Inc. is far larger — about 102× Cassava Sciences Inc's market cap, and DHT Holdings Inc. pays a 19.57% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DHT Holdings Inc. for 1 Days and Cassava Sciences Inc for 37 Days on average.
| DHT | FLNA | |
|---|---|---|
Market Cap | $4.02B | $39.40M |
Volume | 5,493,801 | 759,018 |
Sector | Industrials | Health |
52-Week High | $24.93 | $4.64 |
52-Week Low | $11.20 | $0.68 |
Typical Hold Time | 1 Days | 37 Days |
Enterprise Value | $4.29B | -$43.28M |
Dividend Yield | 19.57% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.
While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
DHT Holdings operates a fleet of crude oil tankers that trade on international routes. Its fleet consists of very large crude carriers, or VLCCs.
Read more on DHT →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →